Who owns Neurocrine Biosciences (NBIX)? Superinvestor holders

5 superinvestors of the 157 tracked here hold Neurocrine Biosciences (NBIX) in their latest 13F filing, with $1.8B between them. Jim Simons (1938–2024) gives it the most weight: 0.44% of the reported portfolio. In their latest reported quarter, Joel Greenblatt and Ray Dalio (founder) added; Jim Simons (1938–2024), Dodge & Cox team and Cliff Asness reduced.

Hold it now
5
of 157 tracked
Combined value
$1.8B
Bought / sold
2 / 3
last quarter

Key facts

Superinvestors holding it
5 of 157
Biggest holder
Dodge & Cox team, $780.8M
Largest weight
Jim Simons (1938–2024), 0.44%of their portfolio
Combined value
$1.8B
Bought last quarter
2
Sold last quarter
3

From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.

Superinvestors holding NBIX, latest filings
#InvestorShare of their portfolioValueSharesLast quarterShares movedQuarter
1Jim Simons (1938–2024)Renaissance Technologies0.44%$326.3M2.3M▼ Reduced 1.5%−35.27KQ3 2026
2Dodge & Cox teamDodge & Cox0.42%$780.8M5.5M▼ Reduced 1.4%−79.86KQ3 2026
3Cliff AsnessAQR Capital Management0.22%$643.5M3.82M▼ Reduced 23%−1.12MQ2 2026
4Joel GreenblattGotham Asset Management0.15%$62.6M371.57K▲ Added 3.2%+11.42KQ2 2026
5Ray Dalio (founder)Bridgewater Associates0.14%$34.7M205.68K▲ Added 39%+57.54KQ2 2026

Quarter by quarter

Superinvestor ownership of NBIX by quarter
QuarterFilings inHoldersCombined sharesCombined valueBoughtSold
Q3 20269227.81M$1.1B02
Q2 2026157614.39M$2.4B33
Q1 2026157516.24M$2.1B41
Q4 2025157412M$1.7B22
Q3 2025157310.75M$1.5B22
Q2 2025157411.18M$1.4B32
Q1 202515638.28M$915.5M30
Q4 2024156610.47M$1.4B51

A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.

Each holder's shares

Shares of NBIX held by each superinvestor, by quarter
InvestorQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Dodge & Cox team5.5M5.58M5.46M5.51M5.56M5.57M5.53M3.02M
Jim Simons (1938–2024)2.3M2.34M2.42M2.24M2.42M2.37M2.5M2.49M
Cliff Asness·3.82M4.94M3.27M2.77M——1.9M
John Overdeck and David Siegel (founders)—2.08M3.06M984.81K————
Joel Greenblatt·371.57K360.14K—————
Ray Dalio (founder)·205.68K—————332.6K
Ken Griffin·————2.05M—2.54M
Israel Englander·————1.19M——
George Soros——————239.82K200K

A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.

Questions and answers

Which superinvestors own NBIX?

In their latest 13F filings: Jim Simons (1938–2024) (0.44% of the portfolio, $326.3M), Dodge & Cox team (0.42% of the portfolio, $780.8M), Cliff Asness (0.22% of the portfolio, $643.5M), Joel Greenblatt (0.15% of the portfolio, $62.6M), Ray Dalio (founder) (0.14% of the portfolio, $34.7M).

Who bought NBIX last quarter?

Joel Greenblatt (added 3.2%), Ray Dalio (founder) (added 39%). “Last quarter” is each investor's latest reported quarter.

Who sold NBIX last quarter?

Reduced: Jim Simons (1938–2024) (1.5% fewer shares), Dodge & Cox team (1.4% fewer shares), Cliff Asness (23% fewer shares).

How current is this?

It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.

Learn

Cite this page

Funkfolio, “Who owns Neurocrine Biosciences (NBIX)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/NBIX/superinvestors

Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.

Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to NBIX by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.